•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) CEO Jeremy Skillington and principal scientist Liam Tremble joined Proactive's Stephen Gunnion to discuss a pivotal moment for the company's lead asset, POLB 001. Tremble explained that the company has secured full regulatory approval from the MHRA, alongside HRA and ARSAC clearances, marking a major milestone that allows the POLB 001 clinical trial to proceed in the UK. He noted that this is “the last regulatory hurdle before we progress to opening up the sites and getting patients screened and into the study,” positioning the company to begin recruitment shortly. With six clinical sites now confirmed, including NHS Lothian and Royal Stoke University Hospital, the study is expected to generate interim data later this summer. The trial is focused on cytokine release syndrome (CRS), an acute condition associated with certain immunotherapies. Tremble highlighted that the risk window occurs early in treatment, meaning data can be gathered quickly. Skillington also outlined insights from independent US payer research, conducted to support discussions with potential partners. The findings confirmed a strong value proposition for POLB 001, with insurers recognising the significant cost burden associated with CRS. He stated that “the findings highlight pricing levels [and] demonstrate that 001 is a multi-billion dollar peak sale potential in the US,” underlining the scale of the opportunity. The company sees POLB 001 as a potential preventative solution in a market with a clear unmet need, strengthening its position ahead of anticipated clinical data and future partnership discussions. Proactive: Jeremy, you also shared insights from independent US payer research. Can you share the rationale for conducting this research? Jeremy Skillington: We conducted the research to support the value proposition for potential partners as we continue discussions. This is a relatively new therapeutic area, so it’s important to get feedback from US payers. These were independently conducted interviews with commercial insurers, Medicare and Medicaid providers, covering over 75 million lives. Proactive: What were the key findings from the research and what do they mean for POLB 001? Jeremy Skillington: The research confirmed a strong and clearly defined value proposition across these payers. Cytokine release syndrome occurs in many CAR-T and bispecific antibody treatments, and there’s no way to predict who will develop it or how severe it will be. When CRS develops, treatment often has to be delayed or stopped, which impacts patient outcomes and increases hospital stays and costs. Prevention could reduce these issues significantly. The insurers recognised the cost burden and assessed what they would be willing to pay to prevent CRS. The findings highlight pricing levels and demonstrate that POLB 001 has multi-billion-dollar peak sales potential in the US. There is a significant market opportunity, and this is compelling for potential partners. Following this, we expect positive data from the clinical trial, and partnership discussions are likely to progress. This represents a strong commercial opportunity alongside the clinical data. Proactive: Well, congratulations on this latest milestone. I hope you'll keep us updated with your progress.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
